1069results about "Optically-active compound separation" patented technology

The present invention is directed to enantioselective polyelectrolyte complex films. Further, said films may be free or isolated membranes, or coatings on substrates such a porous substrates, capillary tubes, chromatographic packing material, and monolithic stationary phases and used to separate chiral compounds. The present invention is also directed to a method for forming such enantioselective polyelectrolyte complex films.

Methods are disclosed which utilize metabolites of bupropion for treating sexual dysfunction.

The invention discloses a method for preparing a compound of a formula (I) or pharmaceutically acceptable salts thereof. The method is characterized by comprising the following steps of: (1) using a compound of a formula (II) as a raw material and carrying out a reduction and amination reaction with an appropriate reducing agent to obtain a compound of a formula (III); (2) using 2-quinary heterocyclic substituted ethanol as a raw material and reacting to obtain a compound of a formula (IV) under the conditions of appropriate reagent, temperature and solvent; (3) after carrying out chiral separation on the compound of the formula (III), carrying out a condensation reaction with the compound of the formula (I) under an alkaline condition to obtain a compound of a formula (V); and (4) carrying out demethylation protection on the compound of the formula (V) under the condition of appropriate temperature and solvent to obtain the compound of the formula (I), wherein R1 in each formula is selected from C1-8 alkyl groups or aromatic bases which can be arbitrarily substituted, X is selected from halogen atoms or p-toluenesulfonic acid groups and methanesulfonic acid groups for protecting alcoholic extract hydroxyl groups, and Y is selected from O, S and N. A target product obtained by the method has high optical purity, convenient operation, lower cost, higher yield and less pollution and is suitable for industrialized production.

The present invention provides an organic amine salt of monatin, or crystal form thereof, and its application as well as a method for resolving the stereoisomers of monatin by forming its salt. The present invention further provides a salt form of monatin that is useful as a sweetening agent or as the active ingredient of a sweetener. The present invention also provides a method for preparing a salt of a particular stereoisomer of monatin with an organic amine by utilizing the difference of crystallinity or solubility of the salt of the stereoisomer of monatin with the organic amine. The present invention also relates to a use of the salt in a method for preparing a metal salt of monatin in which the organic amine is replaced by a metal such as sodium, potassium, or the like.

The invention discloses an axially chiral R-enantiomer and an axially chiral S-enantiomer of the drug Lesinurad. The axially chiral R-enantiomer shows excellent URAT1 inhibition effect, overcomes the problems that a high dosage of Lesinurad racemate leads to renal toxicity and a low dosage Lesinurad racemate cannot produce additional drug effect, and can be applied to treatment or prevention of symptoms of abnormal tissue uric acid levels.

The present invention relates to a method and catalysts for the stereoselective addition of a nucleophile to a reactive π-bond of a substrate. The chiral, non-racemic catalysts of the present invention constitute the first examples of catalysts for nucleophilic additions that comprise a main-group metal and a tri- or tetra-dentate ligand.

The present invention provides a method for producing an enantiomerically enriched α-(phenoxy)phenylacetic acid compound of the formula:

from its enantiomeric mixture, where R¹ is alkyl or haloalkyl and X is halide.

The invention relates to a hydrazone bond-connected chiral covalent organic framework bonded silica gel stationary phase and an application thereof. The stationary phase is prepared by a method comprising the following steps: uniformly mixing a hydrazide chiral precursor, 1,3,5-benzenetricarboxaldehyde and ammoniated silica gel in an organic solvent in an inert atmosphere, carrying out a reaction under the catalysis of acetic acid, and filtering, washing and drying the obtained reaction product to obtain the chiral covalent organic framework bonded silica stationary phase. The structure of the hydrazide chiral precursor is represented by formula (I) shown in the description, a mass ratio of the ammoniated silica gel to the hydrazide chiral precursor is (2-12):1, and molar ratio of the hydrazide chiral precursor to the 1,3,5-benzenetricarboxaldehyde is 1:(0.5-2). The chiral covalent organic framework-bonded silica gel stationary phase is uniform in particle size; and the stationary phase has the advantages of high column efficiency, moderate column pressure and good separation effect on cis-trans isomers and position isomers when used in high performance liquid chromatography, and also has the advantages of definite structure, simple preparation method and good batch reproducibility.

Methods for producing compounds having activity as an α₂δ ligand are provided.

The invention discloses a separating method of optically-active pure isomer 21 (S)-Argatroban, which comprises the following steps: adopting 21(S) and 21(R) Argatroban as raw material; heating to reflux based on mixture of alcohol and water as solvent for 5-10h; cooling; stewing; filtering; obtaining white crystal product; drying; repeating 2-6 times; combining mother liquid; stripping solvent; detecting the content of 21 (S) through high-effect liquid-phase chromatography not less than 98%.

The present invention concerns an improved method and a tray or kit, which is useful to select quickly the optimum resolution agents, combinations and conditions to separate optical isomers. The tray of 24, 48, 96 or more samples is examined simultaneously visually or by standard analytical techniques.

The invention discloses two axial chiral isomers, available medicinal salts thereof, a preparation method thereof, and pharmaceutical application of the two axial chiral isomers or medicinal compositions thereof.

The invention discloses a process method for producing L-2-aminobutanamide hydrochloride serving as an intermediate of levetiracetam, which solves the problem that the conventional produced product has excessively high impurity content or production cost is too high for an enterprise to bear and the like. The method is characterized by comprising the following steps of: reacting propionaldehyde with ammonia water, ammonium chloride and sodium cyanide to obtain 2-amino butyronitrile; hydrolyzing the 2-amino butyronitrile under an alkali condition to obtain 2-aminobutanamide; and splitting the 2-aminobutanamide with L-tartaric acid to obtain the L-2-aminobutanamide hydrochloride. An L-2-amino amides product of which the content is over 99.5 percent is obtained by removing a byproduct, namely, sodium chloride by recrystallization so as to meet the use requirement of foreign customers. The process has the advantages of high yield, high safety and low cost and can be widely suitable for industrialized production of medium-sized and small enterprises.

Process for the synthesis of the compound of formula (I):

Application in the synthesis of ivabradine, addition salts thereof with a pharmaceutically acceptable acid, and hydrates thereof.

The invention relates to a non-interpenetrating chiral MOF (metal organic framework) stationary phase, its preparation method and application in enantiomer separation in HPLC (high-performance liquid chromatography). The stationary phase is a non-interpenetrating chiral three-dimensional porous framework complex with a structural formula as {[ZnL].H2O}n. An asymmetric structural unit {[ZnL].H2O} of the complex is composed of a Zn<2+>, an L ligand and a guest water molecule. The L ligand is -NH- containing chiral pyridine carboxylic acid, its chemical composition is [(N-(4-pyridylmethyl)-L-leucine.HBr)], and its molecular formula is C12H19BrN2O2. Chiral amino acid and 4-pyridylaldehyde are selected as raw materials to synthesize the-NH- containing pyridine carboxylic acid chiral ligand by a one-step process. The ligand and zinc acetate are adopted as raw materials to undergo room temperature diffusion so as to obtain the MOF stationary phase. The material provided in the invention has uniform chiral helical channel, uniform aperture and orifice, and can be used for separation of chiral drugs and other enantiomers. The separation is selectively dependent on the size of a separated enantiomer molecular size, but is not dependent on the functional group of the separated enantiomer. Thus, the non-interpenetrating chiral MOF stationary phase has the characteristics of traditional zeolite molecular sieve separation.

The invention relates to the technical field of medicaments, in particular to a preparation method and application of a bencycloquidium bromide optical isomer. The isomer is obtained by a chemical resolution method, the activity of the isomer is far beyond that of other isomers and racemic forms; when the isomer is taken as a medicament to be taken, the taking dosage is reduced, and side effects caused by other isomers are simultaneously eliminated; moreover, the bencycloquidium bromide optical isomer has a romurtide cyclodextrin inclusion compound with higher pharmaceutical value and a preparation thereof. The romurtide is coated by the cyclodextrin, so that the problems of low water-solubility, unstable preparation prepared by the romurtide cyclodextrin inclusion compound and the like are solved. The romurtide cyclodextrin inclusion compound has the characteristics of high stability, good water-solubility, and low toxic and side effects, and is a quite good immunomodulator.

Disclosed are compounds and derivatives thereof, their synthesis, and their use as Rho-kinase inhibitors. These compounds are useful for inhibiting tumor growth, treating erectile dysfunction, and treating other indications mediated by Rho-kinase, e.g., coronary heart disease.